OBJECTIVE: It is widely accepted that, when feasible, nephron-sparing surgery (NSS) is preferable to radical nephrectomy (RN) for treatment of renal tumors in adults. However, RN is more frequently used in children. We sought to compare in-hospital outcomes after NSS and RN for malignant pediatric renal tumors. MATERIAL AND METHODS: The pediatric health information system (PHIS) combines data from more than 40 North American pediatric hospitals. We queried PHIS to identify children with malignant renal tumors who underwent surgery from 2003 to 2009. We examined whether outcomes (complication rates, cost, and length of stay) differed by procedure type. Multivariate regression models were used to adjust for confounding, and generalized estimating equations were used to adjust for hospital clustering. RESULTS: We identified 1235 children with renal tumors who underwent RN (91%) or NSS (9%). Patients undergoing RN and NSS had similar median comorbidity scores (P = .98), hospital lengths of stay (each 6.0 days, P = .54), in-hospital charges, ($25,700 vs $37,000, P = .11), and surgical complication rates (16.4 vs 20.5%, P = .24). These outcomes remained similar after adjusting for other patient and hospital factors. CONCLUSIONS: Most children with malignant renal tumors treated at children's hospitals undergo RN. RN and NSS use were not significantly different in terms of their length of hospital stay, in-hospital charges, and complication rates. Although oncological outcomes are lacking, these data suggest that NSS may be performed in selected children with malignant renal tumors without significantly increasing their hospital charges, length of stay, or surgical complication rates.
OBJECTIVE: It is widely accepted that, when feasible, nephron-sparing surgery (NSS) is preferable to radical nephrectomy (RN) for treatment of renal tumors in adults. However, RN is more frequently used in children. We sought to compare in-hospital outcomes after NSS and RN for malignant pediatric renal tumors. MATERIAL AND METHODS: The pediatric health information system (PHIS) combines data from more than 40 North American pediatric hospitals. We queried PHIS to identify children with malignant renal tumors who underwent surgery from 2003 to 2009. We examined whether outcomes (complication rates, cost, and length of stay) differed by procedure type. Multivariate regression models were used to adjust for confounding, and generalized estimating equations were used to adjust for hospital clustering. RESULTS: We identified 1235 children with renal tumors who underwent RN (91%) or NSS (9%). Patients undergoing RN and NSS had similar median comorbidity scores (P = .98), hospital lengths of stay (each 6.0 days, P = .54), in-hospital charges, ($25,700 vs $37,000, P = .11), and surgical complication rates (16.4 vs 20.5%, P = .24). These outcomes remained similar after adjusting for other patient and hospital factors. CONCLUSIONS: Most children with malignant renal tumors treated at children's hospitals undergo RN. RN and NSS use were not significantly different in terms of their length of hospital stay, in-hospital charges, and complication rates. Although oncological outcomes are lacking, these data suggest that NSS may be performed in selected children with malignant renal tumors without significantly increasing their hospital charges, length of stay, or surgical complication rates.
Authors: G A McLorie; P H McKenna; M Greenberg; P Babyn; P Thorner; B M Churchill; S Weitzman; R Filler; A E Khoury Journal: J Urol Date: 1991-08 Impact factor: 7.450
Authors: Augusto Zani; Amalia Schiavetti; Marco Gambino; Denis A Cozzi; Andrea Conforti; Francesco Cozzi Journal: J Urol Date: 2005-03 Impact factor: 7.450
Authors: Francesco Cozzi; Amalia Schiavetti; Francesco Morini; Augusto Zani; Marco Gambino; Chiara Donfrancesco; Denis A Cozzi Journal: J Urol Date: 2005-10 Impact factor: 7.450
Authors: Norman E Breslow; Allan J Collins; Michael L Ritchey; Yevgeny A Grigoriev; Susan M Peterson; Daniel M Green Journal: J Urol Date: 2005-11 Impact factor: 7.450
Authors: J R Horwitz; M L Ritchey; J Moksness; N E Breslow; G R Smith; P R Thomas; G Haase; R C Shamberger; J B Beckwith Journal: J Pediatr Surg Date: 1996-08 Impact factor: 2.545
Authors: Paul E Grundy; Norman E Breslow; Sierra Li; Elizabeth Perlman; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Giulio J D'Angio; Milton Donaldson; Max J Coppes; Marcio Malogolowkin; Patricia Shearer; Patrick R M Thomas; Roger Macklis; Gail Tomlinson; Vicki Huff; Daniel M Green Journal: J Clin Oncol Date: 2005-08-29 Impact factor: 44.544
Authors: R C Shamberger; K A Guthrie; M L Ritchey; G M Haase; J Takashima; J B Beckwith; G J D'Angio; D M Green; N E Breslow Journal: Ann Surg Date: 1999-02 Impact factor: 12.969
Authors: Rand N Wilcox Vanden Berg; Emily N Bierman; Megan Van Noord; Henry E Rice; Jonathan C Routh Journal: Urol Oncol Date: 2015-08-05 Impact factor: 3.498
Authors: Michael R Stenger; Jonathan L Slaughter; Kelly Kelleher; Edward G Shepherd; Mark A Klebanoff; Patricia Reagan; Leif D Nelin; William Gardner Journal: Pediatrics Date: 2012-03-12 Impact factor: 7.124
Authors: Henry E Rice; Brian R Englum; Brian C Gulack; Obinna O Adibe; Elizabeth T Tracy; Susan G Kreissman; Jonathan C Routh Journal: Pediatr Blood Cancer Date: 2015-03-21 Impact factor: 3.167
Authors: Steven C Mehl; Megan E Cunningham; Michael D Chance; Huirong Zhu; Sara C Fallon; Bindi Naik-Mathuria; Nicholas A Ettinger; Adam M Vogel Journal: Pediatr Surg Int Date: 2021-12-01 Impact factor: 1.827
Authors: David I Chu; Jessica C Lloyd; Zarine R Balsara; John S Wiener; Sherry S Ross; Jonathan C Routh Journal: J Pediatr Urol Date: 2014-01-22 Impact factor: 1.830